Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...
It’s easy to assume that more data = better models = faster identification. With AI, you can extract associations between ...
The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA ...
After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...
PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...
Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results